31 related articles for article (PubMed ID: 1420814)
1. Changes and significance of the fibrinolytic system following two pulmonary thromboembolisms in a rabbit model.
Liu DC; Duan B; Zhao MN; Wu L; Cao YZ; Liu NB; Xue Z; He ZH; Mi J
J Physiol Pharmacol; 2024 Apr; 75(2):137-144. PubMed ID: 38736261
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model.
Gromotowicz-Poplawska A; Szoka P; Zakrzeska A; Kolodziejczyk P; Marcinczyk N; Szemraj J; Tutka P; Chabielska E
Cells; 2021 Feb; 10(2):. PubMed ID: 33671798
[TBL] [Abstract][Full Text] [Related]
3. Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas.
Hoshino M; Haraguchi Y; Hirasawa H; Sakai M; Saegusa H; Hayashi K; Horita N; Ohsawa H
Crit Care; 2001; 5(2):88-99. PubMed ID: 11299067
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.
de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; Bolt-De Vries J; Benraad TJ; Foekens JA
Br J Cancer; 1999 Apr; 80(1-2):286-94. PubMed ID: 10390010
[TBL] [Abstract][Full Text] [Related]
5. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
Keber D; Stegnar M; Kluft C
Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
[TBL] [Abstract][Full Text] [Related]
6. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
8. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Pedersen OD; Gram J; Jespersen J
Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
[TBL] [Abstract][Full Text] [Related]
10. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
[TBL] [Abstract][Full Text] [Related]
11. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
